UOC
IOVA icon

UBS O'Connor’s Iovance Biotherapeutics IOVA Stock Holding History

UBS O'Connor’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-149,913
Closed -$1.11M – 399
2024
Q4 		$1.11M Buy
149,913
+36,136
+32% +$335K 0.03% 220
2024
Q3 		$1.07M Buy
+113,777
New +$1.08M 0.03% 272
2024
Q1 		– Sell
-104,059
Closed -$1.21M – 560
2023
Q4 		$846K Sell
104,059
-137,915
-57% -$722K 0.03% 290
2023
Q3 		$1.1M Sell
241,974
-47,410
-16% -$310K 0.02% 322
2023
Q2 		$2.04M Sell
289,384
-18,828
-6% -$135K 0.04% 287
2023
Q1 		$1.88M Buy
308,212
+94,677
+44% +$653K 0.04% 331
2022
Q4 		$1.36M Buy
213,535
+10,663
+5% +$83.2K 0.03% 529
2022
Q3 		$1.94M Sell
202,872
-54,000
-21% -$623K 0.02% 631
2022
Q2 		$2.84M Buy
256,872
+202,872
+376% +$2.66M 0.03% 481
2022
Q1 		$899K Buy
+54,000
New +$835K 0.01% 713

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS O'Connor's IOVA Position: Q1 2025 in Review

UBS O'Connor sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 149,913 shares — an estimated $1.11M sold.

UBS O'Connor first reported a position in IOVA in Q1 2022 and held it in 10 quarters. The position peaked at $2.84M in Q2 2022. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • UBS O'Connor reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 149,913 Iovance Biotherapeutics shares in Q1 2025, an estimated $1.11M.
  • UBS O'Connor first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 10 quarters.
  • UBS O'Connor's Iovance Biotherapeutics position peaked at $2.84M in Q2 2022.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.